Michigan HB6101 limits co-pays for insulin products to $35 for a 30-day supply.
Michigan HB6101 amends the state's insurance laws to cap co-pays for insulin products at $35 for each 30-day supply. This applies to all health insurance policies issued or renewed in Michigan after June 30, 2026. The cap must apply to at least one insulin product in each category: rapid-acting, short-acting, intermediate-acting, long-acting, ultra-long-acting, and premixed. Insurers cannot achieve compliance by increasing other cost-sharing requirements or imposing more restrictive treatment limitations. The cap will be adjusted annually based on the Consumer Price Index.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.